97 completed, 46 recruiting, 30 terminated, 26 active not recruiting. 107 Phase 2, 87 Phase 1, 17 Phase 3, 16 Not applicable, 5 Early Phase 1.
Follow Myelofibrosis: new trials by email Literature Review of Myelofibrosis trials Research Report on Myelofibrosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Oral Tetrahydrouridine-Decitabine in Patients With Advanced Myeloproliferative Neoplasms Oral THU-decitabine - Myelofibrosis, MPN - Accelerated or Blast Phase | Phase 2 | Not yet recruiting | John Mascarenhas | 20 | 2027-01-01 | 2026-10-14 |
| Revumenib in Patients With Myelofibrosis Revumenib, Ruxolitinib, FEDRATINIB - Myelofibrosis, Post-polycythemia Vera Myelofibrosis | Phase 1 / Phase 2 | Not yet recruiting | John Mascarenhas | 32 | 2026-12-01 | 2026-07-29 |
| Comparing Momelotinib and Ruxolitinib in People With Untreated Myelofibrosis and Low Blood Cell Counts Momelotinib, Ruxolitinib - Myelofibrosis, Myelofibrosis (MF) | Phase 4 | Not yet recruiting | SWOG Cancer Research Network | 268 | 2026-11-01 | 2026-09-17 |
| Bomedemstat (IMG-7289) in Combination With Momelotinib in Patients With Myelofibrosis bomedemstat - Myelofibrosis | Phase 2 | Not yet recruiting | United Lincolnshire Hospitals NHS Trust | 40 | 2026-11-01 | 2026-02-20 |
| Flonoltinib Maleate Oral Regimens in Patients With Myelofibrosis Flonoltinib Maleate orally - Myelofibrosis, Myelofibrosis Due to and Following Polycythemia Vera | Phase 2 | Not yet recruiting | Chengdu Zenitar Biomedical Technology Co., Ltd | 105 | 2026-11-01 | 2026-10-16 |
| Peri-Transplant Gecacitinib in Patients With Myelofibrosis Undergoing Allogeneic Hematopoietic Stem Cell Transplantation Peri-Transplant Gecacitinib - Myelofibrosis, Primary Myelofibrosis (PMF) | Not applicable | Not yet recruiting | First Affiliated Hospital of Zhejiang University | 46 | 2026-11-01 | 2026-10-29 |
| Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias Pacritinib, Selinexor - Myelofibrosis, Post-polycythemia Vera Myelofibrosis | Phase 2 | Recruiting | John Mascarenhas | 26 | 2026-10-23 | 2026-10-27 |
| Peri-graft Cytokine Profile: Influence of Hematologic Disease and Donor Type Blood sampling - Myelofibrosis, Acute Leukemia | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 96 | 2026-09-15 | 2026-09-04 | |
| A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib Placebo, Elritercept - Myelofibrosis, Anemia | Phase 3 | Recruiting | Takeda | 324 | 2026-09-10 | 2026-10-01 |
| A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant Biospecimen Collection, Electronic Health Record Review, Haploidentical Hematopoietic Cell Transplantation - Accelerated Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia | Phase 1 | Recruiting | City of Hope Medical Center | 46 | 2026-09-09 | 2026-10-23 |
| Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in Myelofibrosis ropeginterferon alfa- 2b, Ruxolitinib - Myelofibrosis | Phase 1 | Recruiting | University of Utah | 15 | 2026-08-21 | 2026-10-19 |
| QT Interval/Corrected QT Interval （QT/QTc） Clinical Study to Evaluate the Cardiac Safety of TQ05105 Tablets in Healthy Participants TQ05105 tablets, Placebo tablets, Moxifloxacin Hydrochloride Tablets - Myelofibrosis | Phase 1 | Active not recruiting | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 60 | 2026-07-30 | 2026-08-07 |
| Study to Evaluate the Effect of Rabeprazole Sodium Enteric-coated Tablets on the Pharmacokinetics of TQ05105 Tablets TQ05105 tablets, Rabeprazole sodium enteric-coated tablets - Myelofibrosis | Phase 1 | Active not recruiting | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 17 | 2026-07-20 | 2026-07-27 |
| A Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of TQ05105 Tablets in Subjects With Intermediate/High-risk Myelofibrosis TQ05105 Tablets (Rovadicitinib Tablets) - Myelofibrosis | Phase 2 | Recruiting | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 51 | 2026-06-18 | 2026-07-15 |
| A Study of Rebecsinib for Patients With Relapsed/Refractory Secondary Acute Myeloid Leukemia or High Risk Myelofibrosis rebecsinib - Secondary AML, Myelofibrosis | Phase 1 | Recruiting | Aspera Biomedicines, Inc. | 28 | 2026-05-21 | 2026-07-20 |
| To Evaluate the Pharmacokinetics and Safety of TQ05105 Tablet in Hepatic Impairment Subjects TQ05105 - Myelofibrosis | Phase 1 | Recruiting | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 24 | 2026-04-01 | 2026-04-06 |
| Momelotinib During and After HCT in Myelofibrosis Momelotinib - Myelofibrosis, Hematopoietic Cell Transplantation (HCT) | Phase 1 | Recruiting | Massachusetts General Hospital | 28 | 2026-02-23 | 2026-03-31 |
| Research Platform Myelofibrosis and Anemia Primary Myelofibrosis, Secondary Myelofibrosis | Recruiting | iOMEDICO AG | 200 | 2026-02-19 | 2026-06-05 | |
| Feasibility Trial of Extracorporeal Iron Purification in Patients With Myelodysplastic Syndrome or Myelofibrosis Low-volume continuous veno-venous haemodialysis with MEX-CD1 use - Myelodysplastic Syndrome, Myelofibrosis | Not applicable | Recruiting | Hospices Civils de Lyon | 13 | 2026-01-06 | 2026-10-13 |
| MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs) Polycythemia Vera, ET (Essential Thrombocythemia) | Recruiting | MPN Research Foundation | 5000 | 2025-09-26 | 2026-01-23 |
Showing 20 of 236. Sign in to see all of them.
Primary Myelofibrosis (236) · Myeloproliferative Disorders (55) · Myelodysplastic Syndromes (54) · Leukemia, Myeloid, Acute (52) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (39) · Leukemia, Lymphocytic, Chronic, B-Cell (36) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (36) · Lymphoma, Non-Hodgkin (34) · Polycythemia Vera (33) · Hodgkin Disease (27) · Multiple Myeloma (26) · Thrombocythemia, Essential (26) · Leukemia, Myelomonocytic, Chronic (22) · Leukemia (16) · Lymphoma (16)
Hemic and Lymphatic Diseases (236) · Bone Marrow Diseases (232) · Hematologic Diseases (231) · Myeloproliferative Disorders (181) · Neoplasms (105) · Neoplasms by Histologic Type (82) · Pathological Conditions, Signs and Symptoms (68) · Pathologic Processes (66) · Leukemia, Myeloid (64) · Leukemia (63) · Disease Attributes (62) · Chronic Disease (60) · Immune System Diseases (60) · Lymphatic Diseases (57) · Immunoproliferative Disorders (56)
ruxolitinib (51) · Cyclophosphamide (19) · fludarabine (17) · fludarabine phosphate (15) · Whole-Body Irradiation (14) · Mycophenolic Acid (13) · Busulfan (12) · Tacrolimus (10) · Stem Cell Transplantation (9) · 11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (8) · fedratinib (8) · Cyclosporine (7) · N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide (7) · Melphalan (6) · Peripheral Blood Stem Cell Transplantation (6)
M.D. Anderson Cancer Center (13) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (10) · Novartis Pharmaceuticals (9) · City of Hope Medical Center (8) · Incyte Corporation (8) · John Mascarenhas (6) · Suzhou Zelgen Biopharmaceuticals Co.,Ltd (6) · Celgene (5) · Bristol-Myers Squibb (4) · Karyopharm Therapeutics Inc (4) · Masonic Cancer Center, University of Minnesota (4) · University of Utah (4) · Center for International Blood and Marrow Transplant Research (3) · FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS (3) · First Affiliated Hospital of Zhejiang University (3)
United States (159) · Italy (51) · Germany (38) · Spain (32) · France (30) · China (28) · United Kingdom (28) · Australia (23) · Canada (23) · Poland (22) · Belgium (21) · Israel (17) · Austria (16) · South Korea (16) · Hungary (13)
John Mascarenhas, MD (7) · Ryotaro Nakamura, MD (4) · Ayalew Tefferi, MD (3) · Marina Kremyanskaya, MD, PhD (3) · Raajit Rampal, MD, PhD (3) · Ronald Hoffman, MD (3) · Brady Stein, MD (2) · Damiano Rondelli, MD (2) · Gabriela Hobbs, MD (2) · Jie Jin, PhD (2) · Josef T Prchal, MD (2) · Kenneth Meehan, MD (2)
PMID 41758981, PMID 10204198, PMID 18997171, PMID 19706886, PMID 19720904, PMID 19812383, PMID 20008298, PMID 20709666, PMID 20709904, PMID 20843246, PMID 22375970, PMID 22718840, PMID 22766223, PMID 22826273, PMID 23682558, PMID 23812932, PMID 23911705, PMID 24056820, PMID 24174625, PMID 24327518, PMID 24355079, PMID 24963042, PMID 25563429, PMID 25762180, PMID 26069290, PMID 26380150, PMID 27247324, PMID 27424289, PMID 27760761, PMID 27931243, PMID 28672195, PMID 28962635, PMID 29073967, PMID 29217781, PMID 29383130, PMID 29544547, PMID 29846250, PMID 30249277, PMID 31101621, PMID 31151984, PMID 31235325, PMID 31533931, PMID 31778911, PMID 31831767, PMID 31869407, PMID 31882719, PMID 31894292, PMID 32017044, PMID 32040960, PMID 32196650
P01CA108671 (8), 2023 (7), 2018 (5), 2015 (3), 2019 (3), P30CA033572 (3), P30CA060553 (2), 2009 (1), 2014 (1), P01CA015396 (1), P01CA229092 (1), P30CA014089 (1), P30CA043703 (1), P50CA100632 (1), R01CA077544 (1)